At present, the performance of MultiCell Technologies, Inc. (OTC:MCET) stock recalls for the saying of elderly people, that “The too good is not as good”.

MCET is rolling down to reflect the fair valuation of investors, though being yet in focus of some stock marketing newsletters.

Last Tuesday, the stock symbol of MultiCell Technologies, Inc. entered the list of top gainers for the day on the OTC.

The price bouncing up of 356.52%, in a day time, bring numerous investor the joy of banking immense gains.

Regrettably, for some of those that entered the market the same day, the astronomical price spike becomes the sword that cut off their profits and maybe even reduced to beggary some of them.

These days, the questions rise “How long MCET may be as attractive as it was one week ago? What is the main factor for such a “dramatic” shares performance?”.

Last Tuesday, MultiCell Technologies, Inc. announced in a press release only, that United States Patent and Trademark Office (USPTO) issued the U.S. patent 7,935,528 and that the company is the worldwide exclusive licensee of it. The patent is related to the isolation and use of human liver stem cells to treat liver disease.

Although, the most advanced product in company's therapeutic pipeline is related to the second generation tricyclic antidepressants, investors appreciated highly the recent news about the treatment of the liver disease, looks not entirely measuring the scale of the financial leverage.

As a result, the skyrocketing MCET recorded its new 52 week high at $0.0245 per share in fifteen times higher than the average for the company trading volume.

As well, stock promoters supported the bullish euphoria.

They sent to many investors stock alerts on MCET.

Though since last week there are no disclosures done about paid MCET promotion, the featuring of company's stock in online stock newsletters continues even as of today.

At the same time, as of today, MultiCell Technologies, Inc. has no any 8k filing done in its SEC disclosures, related to the above spectacular patent's news, oppose to expectations of some investor and requirements of the respective regulatory body.

Further more, these days the performance of MCET looks almost the same as it was at the beginning of the year. Thereon, on a massive attack of stock alerts on MCET, which continued two days and on the absence of company's news shares flew up sharply to plunge down quickly after that. After investor banked gains, MCET started to steam.

As most investor know, one of the advantages of company's “discovery platform” is “the ability to increase the production of adrenaline by selectively modulating noradrenergic neurons..."

The most advanced company's product is a phase 2 therapeutic candidate only. Looks, the company's management may be happy, that its stock successfully passed all stages of development, increasing the production of adrenaline without any modulating of neurons.